MétaCan
Menu
← Back to cohort

Late-breaking abstract: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma

2014· article· en· W1908265276 on OpenAlexaff
Gail M. Gauvreau, Louis‐Philippe Boulet, J. Mark FitzGerald, Donald W. Cockcroft, Beth E. Davis, Richard Leigh, Masaya Tanaka, John Fourre, Makoto Tanaka, Toshiya Nabata, Paul M. O’Byrne

Bibliographic record

VenueEuropean Respiratory Journal · 2014
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsUniversity of CalgaryUniversity of SaskatchewanUniversity of British ColumbiaInstitut universitaire de cardiologie et de pneumologie de QuébecMcMaster University
Fundersnot available
KeywordsMedicineAllergenAsthmaPlaceboImmunologyEosinophilProvocation testAirwayCrossover studyBronchospasmAllergyAnesthesiaPathology

Abstract

fetched live from OpenAlex

Background: The cysteinyl leukotrienes (CysLTs) play a key role in the pathophysiology of asthma. In addition to functioning as potent bronchoconstrictors, CysLTs contribute to airway inflammation through eosinophil and neutrophil chemotaxis, plasma exudation and mucus secretion. Aim: To test the activity of the dual CysLT1/2 antagonist, ONO-6950, against allergen-induced airway responses. Methods: Subjects with documented allergen-induced early (EAR) and late (LAR) asthmatic responses were randomized in a 3-way crossover study to receive ONO -6950 (200 mg) or montelukast (10 mg) or placebo q.d. on Days 1-8 of the 3 treatment periods. Allergen was inhaled on Day 7 and forced expiratory volume in 1 second (FEV 1 ) was measured for 7 hours following challenge. Sputum eosinophils, and airway hyperresponsiveness were measured before and after allergen challenge. The primary outcome was the effect of ONO-6950 versus placebo on the EAR and LAR. Results: Twenty-five non-smoking subjects with mild allergic asthma were enrolled and 20 subjects completed all 3 treatment periods per protocol. ONO-6950 was well tolerated. Compared to placebo, ONO-6950 significantly attenuated the maximum % fall in FEV 1 and area under the %FEV 1 /time curve during the early and late asthmatic responses (p<0.05), and allergen-induced sputum eosinophils. There were no significant differences between ONO-6950 and montelukast. Conclusions: Attenuation of EAR, LAR, and airway inflammation is consistent with CysLT1 blockade. Whether dual CysLT1/2 antagonism offers additional benefit for treatment of asthma requires further study. Funded by ONO Pharmaceutical Co., Ltd., and AllerGen NCE Inc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.262
Teacher spread0.243 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Respiratory Journal→Same topicAsthma and respiratory diseases→French-language works237,207→